Atlas Wealth’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$237K Hold
3,915
0.07% 103
2025
Q4
$211K Buy
+3,915
New +$188K 0.06% 105
2025
Q2
Sell
-3,915
Closed -$239K 111
2025
Q1
$239K Hold
3,915
0.09% 85
2024
Q4
$221K Buy
+3,915
New +$219K 0.08% 87
2024
Q2
Sell
-3,840
Closed -$208K 244
2024
Q1
$208K Hold
3,840
0.1% 75
2023
Q4
$223K Hold
3,840
0.12% 70
2023
Q3
$223K Hold
3,840
0.04% 164
2023
Q2
$238K Hold
3,840
0.04% 164
2023
Q1
$266K Hold
3,840
0.05% 152
2022
Q4
$276K Buy
+3,840
New +$290K 0.07% 102

Other funds holding BMY

Atlas Wealth's BMY Position: Q1 2026 in Review

Atlas Wealth held its Bristol-Myers Squibb (BMY) position steady in Q1 2026 at 3,915 shares worth $237K. The position accounts for 0.07% of the portfolio, ranked #103.

Atlas Wealth first reported a position in BMY in Q4 2022 and has held it in 10 quarters since. The position peaked at $276K in Q4 2022. 2,517 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Atlas Wealth held 3,915 shares of Bristol-Myers Squibb worth $237K as of Q1 2026.
  • Atlas Wealth left its Bristol-Myers Squibb share count unchanged in Q1 2026.
  • Bristol-Myers Squibb made up 0.07% of Atlas Wealth's portfolio in Q1 2026, its #103 holding.
  • Atlas Wealth first reported a position in Bristol-Myers Squibb in Q4 2022 and has held it in 10 quarters since.
  • Atlas Wealth's Bristol-Myers Squibb position peaked at $276K in Q4 2022.
  • 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Atlas Wealth's 13F filing for Q1 2026, filed 6 May 2026.